Management of neonatal candidiasis

Judith L. Rowen, Judy M. Tate

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Objective. To identify areas of consensus and controversy in the management of neonatal candidiasis. Methods. A questionnaire was distributed to US-based members of the Pediatric Infectious Diseases Society and a sampling of US neonatologists. Results. Three hundred eighty evaluable questionnaires were returned (42% of those mailed). Ninety-five percent of respondents have cared for an infant with systemic candidiasis in the past 2 years. Fluconazole and liposomal amphotericin are used to some extent by 90 and 69% of respondents, respectively. A single blood culture positive for Candida led to a recommendation for immediate treatment by 99%; amphotericin B was the preferred therapy for candidemia (88%). More than 80% of respondents would request cerebrospinal fluid, urine and repeat blood cultures and ophthalmologic examination in the evaluation of candidemia. If a cerebrospinal fluid culture is positive, 25% would use amphotericin B alone whereas 62% would add flucytosine. For candiduria Society members chose fluconazole therapy more often than did neonatologists, 23% vs. 3.4% (P < 0.001). There was no consensus concerning duration of therapy, use of an amphotericin B test dose or management of a central catheter in place during candidemia. Conclusions. Systemic candidiasis in neonates is frequently encountered clinical problem. There is agreement that prompt therapy with amphotericin B is required if a blood culture is positive for Candida and that such infants require additional evaluations. Other antifungals (fluconazole, liposomal amphotericin B) are used to some extent in this population. Many issues in management have no clear consensus and warrant further research.

Original languageEnglish (US)
Pages (from-to)1007-1011
Number of pages5
JournalPediatric Infectious Disease Journal
Volume17
Issue number11
StatePublished - Nov 1998

Fingerprint

Candidiasis
Amphotericin B
Candidemia
Fluconazole
Candida
Cerebrospinal Fluid
Therapeutics
Flucytosine
Communicable Diseases
Catheters
Surveys and Questionnaires
Urine
Newborn Infant
Pediatrics
Research
Population
Blood Culture
Systemic candidiasis
Neonatologists

Keywords

  • Amphotericin B
  • Candida
  • Candidiasis
  • Fluconazole
  • Liposomal amphotericin B
  • Neonate
  • Prematurity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Rowen, J. L., & Tate, J. M. (1998). Management of neonatal candidiasis. Pediatric Infectious Disease Journal, 17(11), 1007-1011.

Management of neonatal candidiasis. / Rowen, Judith L.; Tate, Judy M.

In: Pediatric Infectious Disease Journal, Vol. 17, No. 11, 11.1998, p. 1007-1011.

Research output: Contribution to journalArticle

Rowen, JL & Tate, JM 1998, 'Management of neonatal candidiasis', Pediatric Infectious Disease Journal, vol. 17, no. 11, pp. 1007-1011.
Rowen JL, Tate JM. Management of neonatal candidiasis. Pediatric Infectious Disease Journal. 1998 Nov;17(11):1007-1011.
Rowen, Judith L. ; Tate, Judy M. / Management of neonatal candidiasis. In: Pediatric Infectious Disease Journal. 1998 ; Vol. 17, No. 11. pp. 1007-1011.
@article{6a10e05ab4d447e1805386f4886a8226,
title = "Management of neonatal candidiasis",
abstract = "Objective. To identify areas of consensus and controversy in the management of neonatal candidiasis. Methods. A questionnaire was distributed to US-based members of the Pediatric Infectious Diseases Society and a sampling of US neonatologists. Results. Three hundred eighty evaluable questionnaires were returned (42{\%} of those mailed). Ninety-five percent of respondents have cared for an infant with systemic candidiasis in the past 2 years. Fluconazole and liposomal amphotericin are used to some extent by 90 and 69{\%} of respondents, respectively. A single blood culture positive for Candida led to a recommendation for immediate treatment by 99{\%}; amphotericin B was the preferred therapy for candidemia (88{\%}). More than 80{\%} of respondents would request cerebrospinal fluid, urine and repeat blood cultures and ophthalmologic examination in the evaluation of candidemia. If a cerebrospinal fluid culture is positive, 25{\%} would use amphotericin B alone whereas 62{\%} would add flucytosine. For candiduria Society members chose fluconazole therapy more often than did neonatologists, 23{\%} vs. 3.4{\%} (P < 0.001). There was no consensus concerning duration of therapy, use of an amphotericin B test dose or management of a central catheter in place during candidemia. Conclusions. Systemic candidiasis in neonates is frequently encountered clinical problem. There is agreement that prompt therapy with amphotericin B is required if a blood culture is positive for Candida and that such infants require additional evaluations. Other antifungals (fluconazole, liposomal amphotericin B) are used to some extent in this population. Many issues in management have no clear consensus and warrant further research.",
keywords = "Amphotericin B, Candida, Candidiasis, Fluconazole, Liposomal amphotericin B, Neonate, Prematurity",
author = "Rowen, {Judith L.} and Tate, {Judy M.}",
year = "1998",
month = "11",
language = "English (US)",
volume = "17",
pages = "1007--1011",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Management of neonatal candidiasis

AU - Rowen, Judith L.

AU - Tate, Judy M.

PY - 1998/11

Y1 - 1998/11

N2 - Objective. To identify areas of consensus and controversy in the management of neonatal candidiasis. Methods. A questionnaire was distributed to US-based members of the Pediatric Infectious Diseases Society and a sampling of US neonatologists. Results. Three hundred eighty evaluable questionnaires were returned (42% of those mailed). Ninety-five percent of respondents have cared for an infant with systemic candidiasis in the past 2 years. Fluconazole and liposomal amphotericin are used to some extent by 90 and 69% of respondents, respectively. A single blood culture positive for Candida led to a recommendation for immediate treatment by 99%; amphotericin B was the preferred therapy for candidemia (88%). More than 80% of respondents would request cerebrospinal fluid, urine and repeat blood cultures and ophthalmologic examination in the evaluation of candidemia. If a cerebrospinal fluid culture is positive, 25% would use amphotericin B alone whereas 62% would add flucytosine. For candiduria Society members chose fluconazole therapy more often than did neonatologists, 23% vs. 3.4% (P < 0.001). There was no consensus concerning duration of therapy, use of an amphotericin B test dose or management of a central catheter in place during candidemia. Conclusions. Systemic candidiasis in neonates is frequently encountered clinical problem. There is agreement that prompt therapy with amphotericin B is required if a blood culture is positive for Candida and that such infants require additional evaluations. Other antifungals (fluconazole, liposomal amphotericin B) are used to some extent in this population. Many issues in management have no clear consensus and warrant further research.

AB - Objective. To identify areas of consensus and controversy in the management of neonatal candidiasis. Methods. A questionnaire was distributed to US-based members of the Pediatric Infectious Diseases Society and a sampling of US neonatologists. Results. Three hundred eighty evaluable questionnaires were returned (42% of those mailed). Ninety-five percent of respondents have cared for an infant with systemic candidiasis in the past 2 years. Fluconazole and liposomal amphotericin are used to some extent by 90 and 69% of respondents, respectively. A single blood culture positive for Candida led to a recommendation for immediate treatment by 99%; amphotericin B was the preferred therapy for candidemia (88%). More than 80% of respondents would request cerebrospinal fluid, urine and repeat blood cultures and ophthalmologic examination in the evaluation of candidemia. If a cerebrospinal fluid culture is positive, 25% would use amphotericin B alone whereas 62% would add flucytosine. For candiduria Society members chose fluconazole therapy more often than did neonatologists, 23% vs. 3.4% (P < 0.001). There was no consensus concerning duration of therapy, use of an amphotericin B test dose or management of a central catheter in place during candidemia. Conclusions. Systemic candidiasis in neonates is frequently encountered clinical problem. There is agreement that prompt therapy with amphotericin B is required if a blood culture is positive for Candida and that such infants require additional evaluations. Other antifungals (fluconazole, liposomal amphotericin B) are used to some extent in this population. Many issues in management have no clear consensus and warrant further research.

KW - Amphotericin B

KW - Candida

KW - Candidiasis

KW - Fluconazole

KW - Liposomal amphotericin B

KW - Neonate

KW - Prematurity

UR - http://www.scopus.com/inward/record.url?scp=0031737609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031737609&partnerID=8YFLogxK

M3 - Article

C2 - 9849983

AN - SCOPUS:0031737609

VL - 17

SP - 1007

EP - 1011

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 11

ER -